Switching a medicinal ingredient from prescription to non-prescription status guidance document: Closed consultation

Current status: Closed

This consultation ran from April 21, 2022 to June 20, 2022.

Health Canada has updated the current guidance document for companies who wish to submit a request for a change from prescription to non-prescription status to:

The purpose of the consultation was to seek input on the draft revised guidance document.

For more information, please see the accompanying notice.

Who was the focus of this consultation?

Health Canada wished to hear from:

Goals of the consultation

We sought comments from industry and any other interested parties on the usefulness and clarity of the draft revised guidance document. We will use the input gathered from this consultation to improve and finalize the guidance document.

Related information

Contact us

Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Ottawa, ON K1A 0K9
Email: policy_bureau_enquiries@hc-sc.gc.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: